Latest news

Sweden Inhalation Network

18 November, 2020

Nov 18-19 marks the kick off and take off dates for the newly formed Sweden Inhalation Networks. The network is constituted of a small group of scientists with a particular interest in inhaled medicines, that have explored the opportunity to form a Swedish cross disciplinary network. The aim for the network is to maintain and further grow the world class inhalation competence in Sweden. The main targets is to facilitate sharing of inhalation science and

Hidden Gems of the Swedish drug Discovery & Development Pipeline Nov 17

17 November, 2020

Nov 17, Nanologica will take part of the exclusive Swedish-US networking event Hidden Gems of the Swedish Drug Discovery & Development Pipeline. The aim of the event is to bring together a selection of Swedish and Californian companies active in this field, ranging from small highly innovative companies to big pharma and biotech. Organisers include the US Embassy in Sweden, the Swedish Embassy in the US, AmCham, SACC & BIOCOM. The Swedish and Californian drug

Presentation of Nanologica from The Spotlight Next Event, Nov 12 2020

16 November, 2020

Presentation of Nanologica from the Redeye R&D Tools Seminar Nov 10, 2020

13 November, 2020

CEO Andreas Bhagwani presents Nanologica at the Redeye R&D Tools Seminar Nov 10, 2020.

Nanologicas valberedning utsedd inför årsstämman 2021

5 November, 2020

I enlighet med beslut på årsstämman den 28 maj 2020 har styrelsens ordförande kontaktat bolagets tre röstmässigt största ägare eller ägargrupper som var och en har erbjudits att utse en representant att utgöra valberedning i Nanologica AB. De tre största aktieägarna eller ägargrupperna per den 30 september 2020 har utsett var sin representant så att valberedningen inför årsstämman 2021 består av följande tre ledamöter: Thomas Eldered (Flerie Invest AB) – ordförande Mattias Häggblom (Swedbank Robur

Nanologica presenterar på Spotlight Nexts bolagsdag den 12 november

4 November, 2020

Nanologica presenterar på Spotlight Nexts bolagsdag den 12 november kl 15.15. Följ eventet via länken nedan

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.

Categories

News archive